Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
Wang et al., 2024, Cancer Cell 42, 1–16 In the new era of cancer treatment, immunotherapy has become a revolutionary therapeutic approach. Particularly, immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies have significantly improved the survival rates of patients with various types of cancer. Immune checkpoint inhibitors enhance the body’s immune response to cancer […]
Single cell view of tumor microenvironment gradients in pleural mesothelioma
Giotti, B., Dolasia, K., Zhao, W., Cai, P., Sweeney, R., Merritt, E., Kiner, E., Kim, G. S., Bhagwat, A., Nguyen, T., Hegde, S., Fitzgerald, B. G., Shroff, S., Dawson, T., Garcia-Barros, M., Abdul-Ghafar, J., Chen, R., Gnjatic, S., Soto, A., . . . Tsankov, A. M. (2024). Cancer Discovery, 14(11), 2262–2278. https://doi.org/10.1158/2159-8290.cd-23-0017 Immunotherapies have shown […]
Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function
Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., Gunset, G., Giavridis, T., & Sadelain, M. (2023). Cancer Discovery, 14(1), 142–157. https://doi.org/10.1158/2159-8290.cd-22-1319 Suboptimal functional persistence limits the efficacy of adoptive T cell therapies. CD28-based chimeric antigen receptors (CARs) impart potent effector function to […]
Development of a 43 color panel for the characterization of conventional and unconventional T‐cell subsets, B cells, NK cells, monocytes, dendritic cells, and innate …
Sahir, F., Mateo, J. M., Steinhoff, M., & Siveen, K. S. (2020). Cytometry Part A, 105(5), 404–410. https://doi.org/10.1002/cyto.a.24288 Although many flow cytometers can analyze 30–50 parameters, it is still challenging to develop a 40+ color panel for the phenotyping of immune cells using fluorochrome conjugated antibodies due to limitations in the availability of spectrally unique […]